Pyrilinks-D assay

Pyrilinks®-D assay

Osteoporosis An immunoassay that measures deoxypyridinoline–Dpd crosslinks in urine, which are ↑ in osteoporosis. See Deoxypyridinoline.
References in periodicals archive ?
25-29) Pyrilinks-D assay has demonstrated precision and accuracy equal or superior to NTx and linear C telopeptides of type I collagen (CTx).
In combination with Metra's own medical education efforts, the recent launch of our Pyrilinksr-D technology on Chiron Diagnostics' automated immunoassay system and the ongoing development of an in-office Pyrilinks-D assay that will be CLIA-waived, this program advances Metra further toward the goal of broad market awareness and demand for our products.
The US Food and Drug Administration (FDA) has cleared the Pyrilinks-D assay for use as an indicator of bone loss (resorption).
The Pyrilinks-D assay allows physicians to `see' an individual's bone turnover rate and identifies which of their patients may be at risk for increased bone loss," said George W.
The Pyrilinks-D assay received market clearance from the U.
The new Pyrilinks-D assay cassette would be the first cassette developed for the Cholestech L-D-X System to use a specimen other than blood and will utilize immunoassay based technology.
Under the terms of the agreement, Cholestech will be responsible for developing an immunoassay cassette incorporating the Pyrilinks-D assay and obtaining all regulatory clearances prior to marketing.
On January 2, Metra announced receipt of regulatory clearance for its Pyrilinks-D assay as an indicator of bone resorption (loss).
Results suggest that combination of the Pyrilinks-D assay with ultrasonic bone mineral density measurements can provide an accurate tool in screening for patients with accelerated bone loss.
Current research strongly suggests that the Pyrilinks-D assay can be used to increase sensitivity and specificity of potential future mass screening efforts.
Levels of free deoxypyridinoline (free-Dpyr) measured using Metra's Pyrilinks-D assay were higher in patients who experienced a hip fracture than age-matched controls by a statistically significant amount.
We are very excited that the results from this study suggest our Pyrilinks-D assay can help predict which patients may be at increased risk for hip fracture," said George W.